GCP
LPCN icon

GSA Capital Partners’s Lipocine LPCN Stock Holding History

GSA Capital Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,908
Closed -$437K – 1642
2021
Q4 		$437K Buy
25,908
+7,360
+40% +$137K 0.05% 687
2021
Q3 		$344K Buy
18,548
+10,223
+123% +$226K 0.04% 926
2021
Q2 		$198K Buy
8,325
+914
+12% +$21.5K 0.02% 1188
2021
Q1 		$190K Sell
7,411
-3,530
-32% -$102K 0.03% 921
2020
Q4 		$253K Buy
10,941
+6,246
+133% +$150K 0.04% 837
2020
Q3 		$113K Buy
4,695
+1,144
+32% +$30.4K 0.02% 1114
2020
Q2 		$76K Buy
+3,551
New +$46K 0.04% 515

Other funds holding LPCN

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GSA Capital Partners's LPCN Position: Q1 2022 in Review

GSA Capital Partners sold out of Lipocine (LPCN) in Q1 2022, closing a stake of 25,908 shares — an estimated $437K sold.

GSA Capital Partners first reported a position in LPCN in Q2 2020 and held it in 7 quarters. The position peaked at $437K in Q4 2021. 44 funds tracked by Wall St. Rank hold LPCN as of Q1 2022.

  • GSA Capital Partners reported no remaining Lipocine position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 25,908 Lipocine shares in Q1 2022, an estimated $437K.
  • GSA Capital Partners first reported a position in Lipocine in Q2 2020 and held it in 7 quarters.
  • GSA Capital Partners's Lipocine position peaked at $437K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Lipocine as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.